Prime Medicine, Inc. Common Stock (PRME)
Healthcare
Biotechnology
2.90 $
-3.3%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Prime Medicine, Inc. Common Stock (PRME)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 63.7% of the shares are freely tradable; institutional investors hold 66.6%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
66.6%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
23.8%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
63.7%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
23.1%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
181Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Alphabet Inc | 9.17 | 16,562,498 | +0.0 | 03/31/2026 |
| BlackRock Inc | 4.71 | 8,501,708 | +2.8 | 03/31/2026 |
| Vanguard Group Inc | 3.58 | 6,467,872 | +31.4 | 12/31/2025 |
| State Street Corp | 3.51 | 6,345,125 | +24.5 | 03/31/2026 |
| ARK Investment Management LLC | 3.46 | 6,246,827 | +16.4 | 03/31/2026 |
| T. Rowe Price Investment Management,Inc. | 3.04 | 5,481,893 | -22.7 | 03/31/2026 |
| Vanguard Capital Management, LLC | 2.48 | 4,474,162 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| ARK Genomic Revolution | 2.57 | 4,645,932 | -3.0 | 03/31/2026 |
| ARK Genomic Revolution ETF | 2.49 | 4,497,032 | -0.3 | 05/31/2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.45 | 4,432,598 | -0.6 | 05/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.